Overview

Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

Status:
Completed
Trial end date:
2002-10-15
Target enrollment:
Participant gender:
Summary
The objectives of this trial were to investigate the feasibility and the optimal dose of a single administration of Org 36286 to induce monofollicular ovulation in women with WHO Group II anovulatory infertility and to assess the safety (including the absence of antibody formation) of Org 36286.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.